ribosomal protein S6 kinase A4Genealiases: MSK2 · RSK-B · S6K-alpha-4
Q-omics provides the consensus-scored RPS6KA4 profile across patient tissues and cancer cell-line models. RPS6KA4 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPS6KA4 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, RPS6KA4 RNA expression shows 19,083 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where RPS6KA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS6KA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS6KA4 survival associations across molecular data types. RPS6KA4 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS6KA4 RNA expression–survival associations across cancer types. High RPS6KA4 expression shows unfavorable associations in ACC, MESO, KICH, KIRC, LGG and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPS6KA4 RNA expression.
This table summarizes RPS6KA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RPS6KA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS6KA4 shows higher tumor expression in HNSC, KIRC, KIRP, COAD, LIHC and BLCA. The HNSC box plot shows higher RPS6KA4 RNA expression in tumor versus normal tissue (log2 FC = +1.288, t-test p < 0.001).
This table shows molecular features associated with RPS6KA4 in patient tissues and cancer cell lines. In patient samples, RPS6KA4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPS6KA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
